SCHEMBL23588107

SCHEMBL23588107

C=C(Cc1nc(Cc2ccc(-c3ccc(Cl)cc3)cc2)no1)C(=O)OC(C)(C)C

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.45
▸ SMPD1 P17405 2/20 0.44
▸ TSHR P16473 5/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ ERCC1 P07992 1/20 0.42
▸ ERCC4 Q92889 1/20 0.42
▸ NPC1 O15118 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ RAB9A P51151 1/20 0.40
▸ MAPK1 P28482 4/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ L3MBTL1 Q9Y468 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ LMNA P02545 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23578197 0.97 MAPT (0.47) MAPTSMPD1TSHRKDM4EALDH1A1
SCHEMBL23578537 0.87 TRPA1 (0.42) MAPTSMPD1TSHRLMNA
SCHEMBL23578414 0.86 TP53 (0.38) MAPTTSHRALDH1A1HPGDNPC1
SCHEMBL25801776 0.86 MAPT (0.35) MAPTSMPD1TSHRKDM4EALDH1A1
SCHEMBL23578571 0.86 MAPT (0.35) MAPTTSHRALDH1A1MAPK1L3MBTL1
SCHEMBL23578299 0.85 TSHR (0.51) MAPTTSHRKDM4EALDH1A1HTT
SCHEMBL29973380 0.85 TSHR (0.51) MAPTTSHRKDM4EALDH1A1HTT
SCHEMBL23578446 0.85 TRPA1 (0.37) MAPTSMPD1TSHRALDH1A1LMNA
SCHEMBL25801971 0.85 MAPT (0.35) MAPTTSHRKDM4EALDH1A1L3MBTL1
SCHEMBL23578154 0.84 MEN1 (0.40) MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 — — US disclosed
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2023-07-13 — — US disclosed
EP-4081511-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES Sitryx Therapeutics Limited (GB) 2022-11-02 — — EP disclosed
WO-2021130492-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMMATORY PROPERTIES SITRYX THERAPEUTICS LIMITED (GB) 2021-07-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219907-A1 CARBOXY DERIVATIVES WITH ANTIINFLAMATORY PROPERTIES CPA2, RO60, C5AR1 MAPT 4683/4885SMPD1 999/4885TSHR 3550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback